These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine. Scriba M Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688 [TBL] [Abstract][Full Text] [Related]
7. Recent progress in herpes simplex virus immunobiology and vaccine research. Koelle DM; Corey L Clin Microbiol Rev; 2003 Jan; 16(1):96-113. PubMed ID: 12525427 [TBL] [Abstract][Full Text] [Related]
8. Detection of asymptomatic herpes simplex virus infections after vaccination. Ashley R; Mertz GJ; Corey L J Virol; 1987 Feb; 61(2):264-8. PubMed ID: 3806788 [TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. Weinberg A; Merigan TC J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591 [TBL] [Abstract][Full Text] [Related]
10. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094 [TBL] [Abstract][Full Text] [Related]
11. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
12. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. Dix RD; Mills J J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573 [TBL] [Abstract][Full Text] [Related]
13. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Aurelian L; Smith CC; Wachsman M; Paoletti E Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. Bernstein DI; Miller RL; Harrison CJ J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722 [TBL] [Abstract][Full Text] [Related]
17. Mucosal delivery of herpes simplex virus vaccine. Bowen JC; Alpar HO; Phillpotts R; Brown MR Res Virol; 1992; 143(4):269-78. PubMed ID: 1329168 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403 [TBL] [Abstract][Full Text] [Related]
19. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Berman PW; Gregory T; Crase D; Lasky LA Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428 [TBL] [Abstract][Full Text] [Related]
20. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]